Retirement Systems of Alabama Sells 729 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Retirement Systems of Alabama decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 44,650 shares of the medical equipment provider’s stock after selling 729 shares during the period. Retirement Systems of Alabama’s holdings in Zimmer Biomet were worth $4,820,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dunhill Financial LLC grew its stake in shares of Zimmer Biomet by 1,090.0% during the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC purchased a new position in shares of Zimmer Biomet in the third quarter worth about $28,000. Bangor Savings Bank bought a new stake in shares of Zimmer Biomet in the third quarter valued at approximately $31,000. Family Firm Inc. purchased a new stake in shares of Zimmer Biomet during the 2nd quarter valued at approximately $33,000. Finally, Brooklyn Investment Group bought a new stake in Zimmer Biomet during the 3rd quarter valued at $35,000. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Trading Down 0.0 %

Shares of ZBH stock opened at $105.81 on Friday. The business has a 50-day moving average of $108.01 and a 200 day moving average of $108.51. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90. The stock has a market capitalization of $21.06 billion, a PE ratio of 20.12, a P/E/G ratio of 1.96 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the prior year, the firm posted $1.65 earnings per share. The business’s quarterly revenue was up 4.1% compared to the same quarter last year. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 18.25%.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Wells Fargo & Company raised their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Barclays lowered their price target on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a report on Thursday, December 12th. Royal Bank of Canada boosted their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, November 4th. Evercore ISI lowered their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Finally, Wolfe Research assumed coverage on shares of Zimmer Biomet in a research report on Tuesday, September 10th. They set a “peer perform” rating for the company. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $123.33.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.